GLP-1 Drugs Show Promise for Eye Diseases: Anti-Inflammatory and Neuroprotective Effects on Glaucoma and Diabetic Retinopathy

The authors conducted a comprehensive literature review searching for research and clinical trials on GLP-1 receptor agonists in ocular disease published through April 2025. The review covered cellular studies (mechanistic research), animal studies (preclinical models), and clinical observations for glaucoma, diabetic retinopathy, and other ocular conditions. Molecular pathways were analyzed to synthesize the mechanisms of ocular benefit.

Glaucoma and diabetic retinopathy are leading causes of blindness worldwide, and current treatments often address only specific symptoms or pathways. GLP-1 receptor agonists could represent multi-targeted disease-modifying agents that simultaneously address inflammation, oxidative stress, neurodegeneration, and abnormal blood vessel growth — the major drivers of these eye diseases. With millions of people already taking GLP-1 drugs for metabolic conditions, understanding their eye effects has immediate clinical relevance.

The eye is emerging as yet another organ system that benefits from GLP-1 receptor activation — joining the heart, kidneys, liver, and brain. This expanding web of protective effects suggests GLP-1 receptor agonists may be among the most broadly beneficial class of peptide drugs ever developed. The retina, as an extension of the central nervous system, is particularly relevant because it suggests GLP-1 drugs' neuroprotective properties could extend to other neurodegenerative conditions like Alzheimer's and Parkinson's disease.

Most mechanistic evidence comes from cell and animal studies that may not translate directly to human eyes. The clinical evidence for ocular benefits is largely observational (reduced glaucoma incidence in GLP-1 users) rather than from randomized controlled trials designed for eye outcomes. The concern about early diabetic retinopathy worsening adds complexity to clinical decision-making. The review covers a broad topic that may lack depth on individual disease mechanisms. Long-term ocular safety data for GLP-1 drugs is still accumulating.